Connexon Creative - Mammary Cell News 1.19, September 24th, 2009

In this issue: Science News | Current Publications | Industry News | Policy News | Events

TOP STORIES

The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells
Data demonstrate that p53 regulates polarity of cell division in mammary stem cells and suggest that loss of p53 favors symmetric divisions of cancer stem cells, contributing to tumor growth. [Cell]

SPECIAL FEATURE

Mammary Epithelial Cell Colony Interactive Tutorial
Explore interactive bi-potent colonies and highlight luminal and basal structures in 3D morphogenesis structures.
Try tutorial now

SCIENCE NEWS

Distinguishing Breast Cancer-Causing Mutations From Those That Are Harmless
Scientists at the National Cancer Institute at Frederick, have now developed an assay to distinguish harmful BRCA1 mutations from those that are not. [National Cancer Institute, Frederick]

Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Amgen today announced detailed results from a Phase 3, head-to-head trial evaluating Denosumab versus Zometa(R) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. [Amgen, Thousand Oaks]

Treating Bone Loss in Breast Cancer Survivors: Cancer Drugs Aren't the Only Culprits
Loyola University Health System study has found that bone loss can be halted with a comprehensive regimen that includes both osteoporosis drugs and treatments that target secondary causes of bone loss. [Loyola University Health System, Maywood]

Cost of Noncompliance Revealed By Study of Adjuvant Endocrine Treatment for Breast Cancer
The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take Exemestane or Tamoxifen do significantly better than patients who start to take one or other drug but then stop. [Tamoxifen Exemestane Adjuvant Multinational (TEAM)]

CURRENT PUBLICATIONS

LABORATORY RESEARCH

Genetic Heterogeneity of Myc-Induced Mammary Tumors Reflecting Diverse Phenotypes Including Metastatic Potential
A combination of histological and genomic analyses can uncover substantial heterogeneity in mammary tumor formation and therefore highlight aspects of tumor phenotype not evident in the population as a whole. [PNAS]

MUC-1-/ESA+ Progenitor Cells in Normal, Benign and Malignant Human Breast Epithelial Cells
Results show that the MUC-1-/ESA+ subpopulation increases in fibrocystic disease within the hyperplastic areas, and varies in benign and malignant breast tumours, indicating that breast carcinogenesis may develop from malignant changes of normal MUC-1-/ESA+ cells. [Histol Histopathol]

Mouse Mammary Tumor Virus p75 and p110 CUX1 Transgenic Mice Develop Mammary Tumors of Various Histologic Types
Results support the notion that oncogenic activity of CUX1 can facilitate the establishment of a Wnt/Beta-catenin autocrine loop. [Cancer Res]

EpCAM-Targeted Delivery of Nanocomplexed siRNA to Tumor Cells with Designed Ankyrin Repeat Proteins
Researchers report the use of a designed ankyrin repeat protein (DARPin) specific for the epithelial cell adhesion molecule (EpCAM) as a carrier for small interfering RNA (siRNA) complementary to the bcl-2 mRNA. [Mol Cancer Ther]

Development of 'Synthetic Lethal' Strategies to Target BRCA1-Deficient Breast Cancer
Recent clinical trials demonstrating the efficacy of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors for the treatment of BRCA1-deficient breast cancer have provided support for the "synthetic lethal" concept of targeted cancer therapeutics. [Breast Cancer Res]

CLINICAL RESEARCH

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg as First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
First-line Fulvestrant HD was at least as effective as Anastrozole for CBR and ORR and was associated with significantly longer TTP. Fulvestrant HD was generally well tolerated, with a safety profile similar to that of Anastrozole. [J Clin Oncol]

INDUSTRY NEWS

Gamma Medica-Ideas, Inc. Closes $24 Million Financing
Gamma Medica-Ideas, Inc. announced today that it had closed a $24 million financing in order to support continued growth of the company's proprietary imaging system for the improved detection of breast cancer in current and new markets.

STEMCELL Technologies Inc. to Host Stem Cell Training Courses
STEMCELL's fall training program includes includes 2-day courses on mesenchymal stem cell biology, mammary stem cell biology, neural stem cell biology, hematopoietic stem cell biology, and human embryonic and induced pluripotent stem cell biology.

EVENTS

Next Generation Comprehensive Breast Centers of Excellence
September 29-October 2, 2009
Baltimore, MD, United States

2009 National Cancer Research Institute Conference
October 4-7, 2009
Birmingham, United Kingdom

Global Breast Cancer Conference
October 8-10, 2009
Seoul, South Korea

AACR - Advances in Breast Cancer Research
October 13-16, 2009
San Diego, CA, United States

32nd Annual CTRC - AACR San Antonio Breast Cancer Symposium
December 9-13, 2009
San Antonio, TX

Gordon Research Conference - Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

The 21st Meeting of the European Association for Cancer Research
June 26-29, 2010
Oslo, Norway

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Learn more about Mammary Cell News: Archives | Events | Update Profile | Contact Us

This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada